Managing immune checkpoint inhibition in transplant recipients.

Abstract

PD-1 and PD-L1 blockers are immune checkpoint inhibitors that have revolutionised oncology. 1 Hirsch L Zitvogel L Eggermont A Marabelle A PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade. Br J Cancer. 2019; 120: 3-5 Crossref PubMed Scopus (62) Google Scholar However, the benefit–risk ratio of using these drugs in organ transplant recipients, in whom immune checkpoint inhibition can induce intractable allograft rejection, must be finely balanced. Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 studyMaintaining baseline immunosuppression before treatment with an immune checkpoint inhibitor in kidney transplant recipients might not affect expected efficacy and might reduce the risk of allograft rejection mediated by immune checkpoint inhibitors. Full-Text PDF